tiprankstipranks
Akero Therapeutics Inc (AKRO)
NASDAQ:AKRO
US Market

Akero Therapeutics Income Statement

Last quarter (Q3 2024), Akero Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Akero Therapeutics's net income was $-72.70M. See Akero Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ ―$ ―$ ―$ ―$ ―
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ ―$ ―$ ―$ ―$ ―
EBITDA
$ -148.63M$ -111.25M$ -100.74M$ -80.14M$ -43.87M
Operating Income
$ -172.87M$ -115.16M$ -100.89M$ -80.15M$ -45.65M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ -151.76M$ -112.03M$ -100.78M$ -79.21M$ -43.76M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

Akero Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis